Metastatic Cancer Clinical Trial
Official title:
Treatment of Patients With Hepatic Neuroendocrine Metastases Using Drug-Eluting Bead Embolization
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop
the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Infusing doxorubicin beads into the liver, and blocking blood flow to the tumor, may keep
doxorubicin near the tumor and kill more tumor cells.
PURPOSE: This clinical trial is studying the side effects of doxorubicin beads and to see
how well they work in treating patients with unresectable liver metastases from
neuroendocrine tumors.
Status | Active, not recruiting |
Enrollment | 30 |
Est. completion date | June 2015 |
Est. primary completion date | December 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
DISEASE CHARACTERISTICS: Inclusion criteria: - Diagnosis of hepatic neuroendocrine metastases not suitable for radical therapies (e.g., resection or liver transplantation) - Histologically proven neuroendocrine tumor - Tumors are hypervascular based on visual estimation by investigator - Predominant to the liver disease, but extrahepatic disease is not an exclusion - No predominant extrahepatic liver disease - No significant life-threatening extrahepatic disease, in the judgment of the physician - Recent-interval progression of hepatic liver metastases - No diffuse hepatic neuroendocrine metastases defined as massive ill-defined tumor involvement measuring > 90% tumor burden Exclusion criteria: - Clinically evident ascites (a radiographic finding of trace ascites on imaging is acceptable) - Complete occlusion of the entire portal venous system - Evidence of cirrhosis or portal hypertension - Vascular resistance peripheral to the feeding arteries precluding passage of PVA microporous hydrospheres/doxorubicin hydrochloride PATIENT CHARACTERISTICS: Inclusion criteria: - ECOG performance status 0-2 - Must have preserved liver function (Child-Pugh class A-B) without significant liver decompensation - No advanced liver disease (e.g., Child-Pugh C class or active gastrointestinal bleeding, encephalopathy, or ascites [trace ascites is acceptable]), meeting the following criteria: - Bilirubin > 3 mg/dL - AST, ALT, and alkaline phosphatase > 5 times upper limit of normal - Serum creatinine > 2.0 mg/dL - Albumin = 2.0 g/dL - No vascular anatomy or blood that precludes catheter placement or emboli injection - No presence of arteries supplying the lesion not large enough to accept PVA microporous hydrospheres/doxorubicin hydrochloride - No collateral vessel pathways potentially endangering normal territories during embolization - No feeding arteries smaller than distal branches from which they emerge - Not pregnant Exclusion criteria: - See Disease Characteristics - Another active primary tumor - Any contraindication for hepatic embolization procedures, including any of the following: - Porto-systemic shunt - Hepatofugal blood flow - Impaired clotting tests (i.e., platelet count < 50,000/mm³, INR = 1.8, or PTT = 39 seconds) - Renal failure - Severe peripheral vascular disease precluding catheterization - Any contraindication for doxorubicin hydrochloride administration (i.e., serum bilirubin > 5 mg/dL or leukocyte count < 1,500 cells/mm³) - Allergy to contrast media - Intolerant to occlusion procedures - Presence of end arteries leading directly to cranial nerves - Presence or likely onset of hemorrhage - Presence of severe atheromatous disease PRIOR CONCURRENT THERAPY: Exclusion criteria: - Prior anticancer therapy for hepatic neuroendocrine metastases, except previous surgical therapy - Any continuing complication or prior cancer therapy that has not improved or resolved prior to 21 days before start of treatment, if the investigator determines that the continuing complication will compromise the safety of the patient after treatment with PVA microporous hydrospheres/doxorubicin hydrochloride - Presence of patent extra-to-intracranial anastomoses or shunts - Use of PVA microporous hydrospheres/doxorubicin hydrochloride in the following applications: - Embolization of large-diameter arteriovenous shunts - Pulmonary arterial vasculature - Any vasculature where the use of PVA microporous hydrospheres/doxorubicin hydrochloride could pass directly into the internal carotid artery or the above-listed vessels - Concurrent enrollment in another clinical study |
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Baltimore | Maryland |
Lead Sponsor | Collaborator |
---|---|
Sidney Kimmel Comprehensive Cancer Center | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Tumor response (efficacy) | Time to progression | No | |
Primary | Safety | 30 days post study exit | Yes | |
Secondary | Survival | overall survival | No | |
Secondary | Biochemical response | Time to progression | No | |
Secondary | Symptomatic response | Time to progression | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Recruiting |
NCT05798611 -
Study of ART0380 in Patients With Biologically Selected Solid Tumors
|
Phase 2 | |
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Recruiting |
NCT05566574 -
A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05036681 -
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
|
Phase 2 | |
Withdrawn |
NCT00005030 -
SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the Liver
|
Phase 1 | |
Recruiting |
NCT05525858 -
KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
|
||
Recruiting |
NCT04085029 -
Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry
|
||
Recruiting |
NCT06058988 -
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
|
Phase 2 | |
Not yet recruiting |
NCT05981170 -
Rurality Adapted Physical Activity Sport Health
|
||
Not yet recruiting |
NCT03058809 -
Evaluation of Viatar™ Oncopheresis System in Removing CTC From Whole Blood
|
Phase 1/Phase 2 | |
Completed |
NCT02529553 -
A Study of LY3076226 in Participants With Advanced or Metastatic Cancer
|
Phase 1 | |
Terminated |
NCT01929941 -
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
|
Phase 1 | |
Completed |
NCT01302808 -
Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
|
Phase 1 | |
Terminated |
NCT00918645 -
Calcium-41 (41Ca) Chloride Aqueous Solution in Diagnosing Patients With Prostate Cancer and Bone Metastasis
|
N/A | |
Completed |
NCT00795678 -
Chemotherapeutic Agents in Brain/Breast
|
N/A | |
Withdrawn |
NCT00769990 -
Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases
|
Phase 1/Phase 2 | |
Completed |
NCT00557102 -
Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung
|
Phase 2 | |
Recruiting |
NCT00398437 -
Magnetic Resonance Imaging for the Early Detection of CNS Metastases in Women With Stage IV Breast Cancer
|
N/A |